Total amount: € 0,00
HOW TO ORDER
A Journal on Heart and Vascular Diseases
Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752
Minerva Cardioangiologica 2017 Apr 10
Copyright © 2017 EDIZIONI MINERVA MEDICA
Differential effects of phosphodiesterase-5 inhibition in chronic cardiac decompensation, depending on the type, whether HFREF or HFpEF, of heart failure: a meta-analysis
Renato DE VECCHIS 1 ✉, Arturo CESARO 2, Carmelina ARIANO 1
1 Cardiology Unit, Presidio Sanitario Intermedio "Elena d'Aosta", ASL Napoli 1 Centro, Naples, Italy; 2 Department of Cardiology, Second University of Napoli, Monaldi Hospital, Naples, Italy
INTRODUCTION: According to 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension(PH), no specific drug is currently indicated for PH related to left heart disease( PH-LDH), i.e., the one secondary to left chronic heart failure (CHF), which coincides with the group 2 of the PH classification endorsed by the above-mentioned guidelines. In fact, adoption of therapies that specifically apply for so-called pulmonary arterial hypertension (group 1 of the PH classification) has been regarded as substantially contraindicated in patients with PH- LHD, according to current ESC/ERS guidelines. Nevertheless, based on some previous studies, phosphodiesterase- 5 (PDE5) inhibitors would seem to exert a beneficial effect in CHF patients, although the comparison between these studies shows quite inconsistent or heterogeneous findings. Thus, in order to better evaluate the effect of PDE5i therapy in CHF patients, we performed a meta-analysis of randomized controlled trials ( RCTs).
EVIDENCE ACQUISITION: We searched PubMed and EMBASE electronic archives for RCTs that compared PDE5i with placebo in CHF with reduced (HFREF) or preserved (HFpEF) left ventricular ejection fraction. The endpoints of interest were: a composite of all-cause death or hospitalization, adverse events, peak VO2 , 6-minutes walking distance (6MWD), left ventricular ejection fraction (LVEF), E/e’ ratio, mean pulmonary arterial pressure (mPAP), pulmonary arterial systolic pressure (PASP)and pulmonary vascular resistance (PVR).
EVIDENCE SYNTHESIS: 14 studies, enrolling a total of 928 patients, were comprised in the meta- analysis. Among these, 13 were RCTs and one was a subgroup analysis. Among patients with HFREF( no.555), a significant benefit was conferred by PDE5i against the risk of the composite endpoint of death and hospitalization (OR= 0.28; 95% CI: 0.10 to 0.74; p =0.03) . Furthermore, among HFREF patients, therapy with PDE5i improved peak VO2 ( difference in means [MD]=3.76 ml/min/kg; 95% CI: 3.27 to 4.25)as well as 6MWD(MD= 22.7 meters ; 95% CI: 8.19 to 37.21 ) and LVEF (MD= 4.30%; 95% CI: 2.18% to 6.42%). For patients with HFREF, PDE5i therapy yielded a nonsignificant decrease in mPAP, while PASP was significantly reduced (MD: -11.52 mmHg; 95% CI: -15.56 to -7.49; p <0.001). By contrast, in the RCTs of patients with HFpEF(no.373), no benefit ensued from PDE5i use regarding all of the investigated clinical, ergospirometric or hemodynamic endpoints.
CONCLUSIONS: Therapy with PDE5i caused a statistically significant improvement of clinical outcomes, exercise capacity and pulmonary hemodynamics in patients with HFREF , but not in HFpEF. However, in view of the relatively small sample size of the HFpEF population recruited so far in the RCTs that investigated the effects of PDE5i treatment , further research in this field is required to clarify whether PDE5 inhibitors are really beneficial even in this subset.
KEY WORDS: Sildenafil - Phosphodiesterase-5 inhibitors - Heart failure - Pulmonary hemodynamics - Meta-analysis